|
Market Cap | 159.56M | EPS (ttm) | -2.30 |
P/E | - | EPS this Y | -10.46% |
Forward P/E | - | EPS next Y | -6.87% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 1.16 | EPS Q/Q | -48.75% |
Dividend | - | Sales Q/Q | - |
Insider Own | 45.84% | Inst Own | 59.78% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 4.04% | Earnings | Mar 28/b |
Analyst Recom | 1.00 | Target Price | 19.33 |
Avg Volume | 74.15K | 52W Range | 3.19 - 14.39 |
|
|
Today 08:00AM
|
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
(GlobeNewswire) +11.68% |
Mar-05-24 04:30PM
|
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
(GlobeNewswire) |
Mar-04-24 08:00AM
|
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
(GlobeNewswire) -11.40% |
Feb-27-24 08:00AM
|
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
(GlobeNewswire) +22.07% |
Feb-08-24 08:00AM
|
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magov evi -Liebisch, Ph.D., J.D., to Board of Directors
(GlobeNewswire) |
Feb-06-24 08:00AM
|
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
(GlobeNewswire) |
Jan-12-24 04:00PM
|
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) |
Jan-04-24 08:00AM
|
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire) -6.63% |
Jan-03-24 08:00AM
|
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
(GlobeNewswire) |
Nov-28-23 08:00AM
|
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
(GlobeNewswire) |
|
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Chione Ltd | 10% Owner | Jun 26 '23 | Sale | 12.93 | 16 | 207 | 3,848,632 | Jun 28 03:47 PM | Holm-Jorgensen Rasmus | Chief Financial Officer | Jun 16 '23 | Option Exercise | 3.63 | 9,500 | 34,485 | 29,530 | Jun 20 05:21 PM | Chione Ltd | 10% Owner | Jun 15 '23 | Sale | 12.14 | 2,056 | 24,960 | 3,848,648 | Jun 20 05:15 PM | Chione Ltd | 10% Owner | Jun 14 '23 | Sale | 12.13 | 893 | 10,832 | 3,850,704 | Jun 14 06:33 PM | Chione Ltd | 10% Owner | Jun 13 '23 | Sale | 12.30 | 3,000 | 36,900 | 3,851,597 | Jun 14 06:33 PM |
|
|
|
|
Market Cap | 80.77M | EPS (ttm) | -0.85 |
P/E | - | EPS this Y | -21.36% |
Forward P/E | - | EPS next Y | 43.21% |
PEG | - | EPS past 5Y | 4.02% |
P/S | 4.06 | EPS next 5Y | - |
P/B | 9.99 | EPS Q/Q | -59.53% |
Dividend | - | Sales Q/Q | -85.76% |
Insider Own | 13.11% | Inst Own | 27.50% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 1.32% | Earnings | Mar 28/b |
Analyst Recom | 1.00 | Target Price | 4.50 |
Avg Volume | 95.34K | 52W Range | 2.23 - 11.10 |
|
|
|
Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. |
|
|
|
Market Cap | 0.97M | EPS (ttm) | -13.10 |
P/E | - | EPS this Y | 93.57% |
Forward P/E | - | EPS next Y | 89.86% |
PEG | - | EPS past 5Y | 49.72% |
P/S | 0.05 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 98.98% |
Dividend | - | Sales Q/Q | 121.92% |
Insider Own | 3.90% | Inst Own | 8.53% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 7.79% | Earnings | Mar 28/b |
Analyst Recom | 3.00 | Target Price | 5.00 |
Avg Volume | 734.85K | 52W Range | 0.20 - 12.25 |
|
|
|
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ. |
|
| |
|
Market Cap | 52.53M | EPS (ttm) | -0.03 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 6.59 | EPS Q/Q | -476.06% |
Dividend | - | Sales Q/Q | - |
Insider Own | 73.62% | Inst Own | 1.80% |
Insider Trans | 0.00% | Inst Trans | 10.68% |
Short Float | 0.81% | Earnings | Mar 28/b |
Analyst Recom | - | Target Price | - |
Avg Volume | 9.56K | 52W Range | 4.78 - 39.60 |
|
|
|
American Oncology Network, Inc. engages in the provision of community-based oncology management. The company was founded on November 17, 2020 and is headquartered in Fort Myers, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Saba Capital Management, L.P. | 10% Owner | Sep 25 '23 | Sale | 10.50 | 205,512 | 2,157,876 | 0 | Sep 25 05:59 PM |
|
|
|
|
Market Cap | 53.72M | EPS (ttm) | - |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 0.07 | EPS Q/Q | -1366.67% |
Dividend | - | Sales Q/Q | - |
Insider Own | 27.31% | Inst Own | 0.31% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.07% | Earnings | Mar 28/b |
Analyst Recom | 1.00 | Target Price | 17.00 |
Avg Volume | 234.52K | 52W Range | 0.52 - 49.00 |
|
|
|
Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in 2015 and is headquartered in Foster City, CA. |
|
| |
|
Market Cap | 1.90B | EPS (ttm) | 0.43 |
P/E | 40.99 | EPS this Y | 2018.56% |
Forward P/E | 16.10 | EPS next Y | 45.02% |
PEG | 1.84 | EPS past 5Y | - |
P/S | 3.54 | EPS next 5Y | 22.22% |
P/B | 9.45 | EPS Q/Q | 100.85% |
Dividend | 0.46% | Sales Q/Q | 82.63% |
Insider Own | 3.33% | Inst Own | 20.62% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.34% | Earnings | Mar 28/b |
Analyst Recom | 1.00 | Target Price | 29.60 |
Avg Volume | 521.32K | 52W Range | 14.80 - 27.50 |
|
|
|
Atour Lifestyle Holdings Ltd. engages in the development of lifestyle brands around hotel. The company was founded by Hai Jun Wang on April 10, 2012 and is headquartered in Shanghai, China. |
|
|
|
Market Cap | 91.16M | EPS (ttm) | -2.77 |
P/E | - | EPS this Y | 57.32% |
Forward P/E | - | EPS next Y | 22.59% |
PEG | - | EPS past 5Y | 10.97% |
P/S | 20.08 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 20.10% |
Dividend | - | Sales Q/Q | -52.05% |
Insider Own | 7.14% | Inst Own | 56.27% |
Insider Trans | 8.24% | Inst Trans | -0.33% |
Short Float | 9.19% | Earnings | Mar 28/b |
Analyst Recom | 2.60 | Target Price | 4.83 |
Avg Volume | 3.19M | 52W Range | 0.20 - 3.08 |
|
|
|
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Touchon Pascal | President and CEO | Mar 04 '24 | Sale | 0.72 | 24,844 | 17,888 | 1,910,652 | Mar 06 06:19 PM | Nguyen AnhCo | EVP, Chief Sci. & Tech Officer | Mar 04 '24 | Sale | 0.72 | 10,746 | 7,737 | 941,397 | Mar 06 06:18 PM | Murugan Amar | EVP, Chief Legal Officer | Mar 04 '24 | Sale | 0.72 | 10,044 | 7,232 | 727,521 | Mar 06 06:18 PM | Henrich Jill | EVP, Global Head RA & Quality | Mar 04 '24 | Sale | 0.72 | 3,879 | 2,793 | 555,001 | Mar 06 06:16 PM | Touchon Pascal | President and CEO | Nov 16 '23 | Sale | 0.39 | 20,409 | 7,939 | 655,496 | Nov 20 05:31 PM |
|
|
| |
|
Market Cap | 892.88M | EPS (ttm) | -2.22 |
P/E | - | EPS this Y | 66.09% |
Forward P/E | 10.44 | EPS next Y | 178.09% |
PEG | - | EPS past 5Y | - |
P/S | 0.25 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 13.94% |
Dividend | - | Sales Q/Q | 20.68% |
Insider Own | - | Inst Own | 21.72% |
Insider Trans | - | Inst Trans | -0.94% |
Short Float | 3.12% | Earnings | Mar 28/b |
Analyst Recom | 1.92 | Target Price | 14.54 |
Avg Volume | 1.25M | 52W Range | 5.80 - 13.86 |
|
|
|
Azul SA is a holding company, which engages in the provision of airline passenger and cargo services. The firm's service features include passenger seat selection, leather seats, individual entertainment screens with free live television at every seat in all E-Jets, extensive legroom with a pitch of 30 inches or more, complimentary beverage and snack services and free bus service to key airports. The company was founded by David Neeleman on January 03, 2008 and is headquartered in Barueri, Brazil. |
|
|
|
Market Cap | 391.06M | EPS (ttm) | -0.49 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 23.77 | EPS next 5Y | - |
P/B | 2.29 | EPS Q/Q | -2363.31% |
Dividend | - | Sales Q/Q | - |
Insider Own | 69.89% | Inst Own | 11.49% |
Insider Trans | 0.00% | Inst Trans | 0.26% |
Short Float | 2.38% | Earnings | Mar 28/b |
Analyst Recom | - | Target Price | - |
Avg Volume | 1.31M | 52W Range | 0.34 - 62.91 |
|
|
|
Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Tuffin Paula | General Counsel and CCO | Feb 01 '24 | Option Exercise | 0.00 | 129,600 | 0 | 129,600 | Feb 05 05:52 PM | RYAN KEVIN J | Chief Financial Officer | Feb 01 '24 | Option Exercise | 0.00 | 3,088,000 | 0 | 3,088,000 | Feb 06 05:07 PM |
|
|
|
|
Market Cap | 17.14M | EPS (ttm) | 0.36 |
P/E | 8.20 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -0.86% |
P/S | 0.38 | EPS next 5Y | - |
P/B | 0.93 | EPS Q/Q | 7.53% |
Dividend | - | Sales Q/Q | 8.51% |
Insider Own | 15.98% | Inst Own | 16.05% |
Insider Trans | 0.00% | Inst Trans | -2.27% |
Short Float | 0.54% | Earnings | Mar 28/b |
Analyst Recom | - | Target Price | - |
Avg Volume | 10.21K | 52W Range | 2.32 - 4.16 |
|
|
|
BOS Better Online Solutions Ltd. provides intelligent robotics and supply chain solutions to enterprises. It offers smart automation systems for industrial processes, logistics and retail stores. The firm operates through the following segments: Intelligent Robotics, Radio Frequency Identification (RFID), and Supply Chain Solutions. The company was founded by Israel Gal in 1990 and is headquartered in Rishon LeZion, Israel. |
|
|